Status: Recruiting
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18-60Biological sex: AllType: InterventionalSponsor: jCyte, IncUpdated: Apr 13, 2026Locations: 14
Eligibility criteria
Clinical diagnosis of RP supported by at least 2 of the following clinical findi... [+16]
Participation in any clinical trial of a drug intervention within the last 6 mon... [+16]